Gaush Meditech Valuation
Is F7Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of F7Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: F7Y (€1.22) is trading above our estimate of fair value (€0.68)
Significantly Below Fair Value: F7Y is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for F7Y?
Key metric: As F7Y is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is F7Y's PE Ratio? | |
|---|---|
| PE Ratio | 15.5x |
| Earnings | CN¥90.70m |
| Market Cap | CN¥1.41b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | 5.7x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does F7Y's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 22.3x | ||
PUS PULSION Medical Systems | 26.7x | n/a | €134.4m |
SBS Stratec | 32.1x | 25.4% | €336.7m |
DRW3 Drägerwerk KGaA | 7.2x | 2.0% | €790.3m |
EUZ Eckert & Ziegler | 23.2x | 5.9% | €770.9m |
F7Y Gaush Meditech | 15.5x | n/a | €1.5b |
Price-To-Earnings vs Peers: F7Y is good value based on its Price-To-Earnings Ratio (15.5x) compared to the peer average (22.2x).
Price to Earnings Ratio vs Industry
How does F7Y's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: F7Y is good value based on its Price-To-Earnings Ratio (15.5x) compared to the European Medical Equipment industry average (29.1x).
Price to Earnings Ratio vs Fair Ratio
What is F7Y's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15.5x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate F7Y's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Shandong Weigao Group Medical Polymer
HK$20.7b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.54
7D
-1.8%
1Y
-37.1%
Fagron
€1.3b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
4A5
€18.18
7D
-2.7%
1Y
6.1%
LNA Santé
€242.3m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-6.8%
1Y
15.7%